Armata Pharmaceuticals: Gains on U.S. defense department funding for drug development

Armata Pharmaceuticals

17/06/2020 14:22

** Shares of drug maker Armata Pharmaceuticals  ARMP.A 
surge 51.36% pre-market to $5.57 per share, on track to open at
their 13-month high
    ** Co says it received a $15 mln award from the U.S.
Department of Defense for a clinical study of its second
phage-based therapeutic candidate, AP-SA02, for use in the
treatment of complicated Staphylococcus aureus bacteremia
infections   urn:newsml:reuters.com:*:nPn1W7DKSa
    ** Co says clinical trials of bacteremia study to not start
prior to mid-2021
    ** Shares on track to record biggest single day gain in the
past four months on opening
    ** Stock gained 12.53% this year through Tuesday's close

 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.nayar@thomsonreuters.com))